SecBot SecBot
8-K ·Filed Apr 6, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001193125-26-142904
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▲ Bullish

Traders should monitor the progress of regulatory approvals and the tender offer, as the deal is expected to close within 90 days. The acquisition significantly strengthens Neurocrine's portfolio in endocrinology and rare disease, with VYKATTM XR providing a durable platform for long-term value creation. The stock may react positively to the deal's closure and any updates on VYKATTM XR's commercial performance under Neurocrine's commercial infrastructure.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$131.69
T+0 close · Apr 6, 2026 · via day close
Latest settled
+27.40%
T+60 · $167.77
Vs SPY
+14.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $131.69entry
  2. T+1 · 7mo ago −0.60%α −0.66% · $130.90
  3. T+5 · 7mo ago −4.07%α −8.21% · $126.32
  4. T+20 · 7mo ago +1.74%α −7.24% · $133.98
  5. T+60 · 5mo ago +27.40%α +14.23% · $167.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neurocrine Biosciences (NBIX) has entered into a definitive agreement to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition will add VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio of first-in-class medicines, strengthening its leadership in endocrinology and rare disease. The deal is expected to close within 90 days, subject to customary closing conditions including regulatory approvals.

Key Financial Metrics

Deal Value
$2.9B
Premium
34%
Deal Type
acquisition

Key Facts

  • Neurocrine Biosciences is acquiring Soleno Therapeutics for $53.00 per share in cash.
  • The total transaction equity value is $2.9 billion.
  • The acquisition adds VYKATTM XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's portfolio.
  • VYKATTM XR generated $190 million in revenue for Soleno in 2025.
  • The deal is expected to close within 90 days, subject to customary closing conditions including regulatory approvals.
  • Neurocrine will fund the transaction with cash on hand and plans to take on a modest amount of pre-payable debt.
  • Soleno's board of directors recommends that stockholders accept the offer and tender their shares.
  • The acquisition strengthens Neurocrine's leadership in endocrinology and rare disease and adds a first-in-class therapy with durable value creation potential.

Financial Impact

The acquisition represents a $2.9 billion equity purchase price, with VYKATTM XR contributing $190 million in 2025 revenue to Soleno. Neurocrine expects the deal to immediately enhance its growth profile and diversify its revenue base.

revenuedilutiondebt

Risk Factors

  • The transaction is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
  • There is uncertainty around how many of Soleno's stockholders will tender their shares in the offer.
  • Integration risks and potential disruption to business operations could impact the realization of anticipated benefits.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142904
Document: d110123dex101.htm0001193125-26-142904
Document: d110123d8k.htm0001193125-26-142904
Document: d110123dex991.htm0001193125-26-142904
Document: d110123dex992.htm0001193125-26-142904
Document: 0001193125-26-142904-index-headers.html0001193125-26-142904
Document: 0001193125-26-142904-index.html0001193125-26-142904
Document: 0001193125-26-142904.txt0001193125-26-142904

Track record

30 reports on NBIX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +27.35% at T+20 after the Oct 15, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 7h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026